KR100376306B1 - Healthy food for promoting the circuration of the blood - Google Patents
Healthy food for promoting the circuration of the blood Download PDFInfo
- Publication number
- KR100376306B1 KR100376306B1 KR10-2000-0045721A KR20000045721A KR100376306B1 KR 100376306 B1 KR100376306 B1 KR 100376306B1 KR 20000045721 A KR20000045721 A KR 20000045721A KR 100376306 B1 KR100376306 B1 KR 100376306B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- blood circulation
- blood
- promoting
- present
- Prior art date
Links
- 230000001737 promoting effect Effects 0.000 title claims abstract description 26
- 210000004369 blood Anatomy 0.000 title description 7
- 239000008280 blood Substances 0.000 title description 7
- 235000001497 healthy food Nutrition 0.000 title description 2
- 230000017531 blood circulation Effects 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 235000013402 health food Nutrition 0.000 claims abstract description 15
- 210000003056 antler Anatomy 0.000 claims abstract description 9
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 8
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 8
- 241000282994 Cervidae Species 0.000 claims abstract description 6
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 4
- 240000008042 Zea mays Species 0.000 claims abstract 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract 3
- 235000005822 corn Nutrition 0.000 claims abstract 3
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 9
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 9
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 9
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 9
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 9
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 9
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 9
- 240000000171 Crataegus monogyna Species 0.000 claims description 9
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 9
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 9
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 9
- 239000002023 wood Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 22
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 10
- 241000209020 Cornus Species 0.000 abstract description 10
- 206010019233 Headaches Diseases 0.000 abstract description 7
- 208000035475 disorder Diseases 0.000 abstract description 6
- 231100000869 headache Toxicity 0.000 abstract description 5
- 238000001467 acupuncture Methods 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 3
- 240000007049 Juglans regia Species 0.000 abstract 1
- 235000009496 Juglans regia Nutrition 0.000 abstract 1
- 235000020234 walnut Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 206010020772 Hypertension Diseases 0.000 description 13
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 235000013305 food Nutrition 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- 208000007101 Muscle Cramp Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 239000009429 Ginkgo biloba extract Substances 0.000 description 3
- -1 P-chimol Chemical compound 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- 235000007173 Abies balsamea Nutrition 0.000 description 2
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 239000004857 Balsam Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
- 244000018716 Impatiens biflora Species 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- PXOYOCNNSUAQNS-AGNJHWRGSA-N alantolactone Chemical compound C1[C@H]2OC(=O)C(=C)[C@H]2C=C2[C@@H](C)CCC[C@@]21C PXOYOCNNSUAQNS-AGNJHWRGSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 210000001627 cerebral artery Anatomy 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- MIJYXULNPSFWEK-LGSDIRQTSA-N (4as,6as,6br,10r,12ar)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C1C[C@@H](O)C(C)(C)C2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)CC5C4=CCC3[C@]21C MIJYXULNPSFWEK-LGSDIRQTSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- FMIMFCRXYXVFTA-UHFFFAOYSA-N 3-Oxo-12-oleanen-28-oic acid Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C FMIMFCRXYXVFTA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NLZCOTZRUWYPTP-MIUGBVLSSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLZCOTZRUWYPTP-MIUGBVLSSA-N 0.000 description 1
- YFVGIJBUXMQFOF-PJOVQGMDSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 YFVGIJBUXMQFOF-PJOVQGMDSA-N 0.000 description 1
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 240000004510 Agastache rugosa Species 0.000 description 1
- 235000010686 Agastache rugosa Nutrition 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 241001346320 Amomum villosum var. xanthioides Species 0.000 description 1
- 235000016500 Amomum xanthioides Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 244000277285 Cassia obtusifolia Species 0.000 description 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010085330 Estradiol Receptors Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 244000116484 Inula helenium Species 0.000 description 1
- 235000002598 Inula helenium Nutrition 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- YFVGIJBUXMQFOF-SAXLCNSLSA-N Linarin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 YFVGIJBUXMQFOF-SAXLCNSLSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- SYTRJRUSWMMZLV-VQGWEXQJSA-N Matricin Chemical compound [C@@H]1([C@H](CC(C)=C2[C@@H]3[C@](C=C2)(C)O)OC(C)=O)[C@@H]3OC(=O)[C@H]1C SYTRJRUSWMMZLV-VQGWEXQJSA-N 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- CGMGCGYLRFAMQF-CHHVJCJISA-N Puerarol Natural products O=C1Oc2c(-c3oc4c(c13)ccc(O)c4)cc(C/C=C(\CC/C=C(\C)/C)/C)c(O)c2 CGMGCGYLRFAMQF-CHHVJCJISA-N 0.000 description 1
- 241000282374 Puma concolor Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000609829 Rubus sachalinensis Species 0.000 description 1
- 240000005499 Sasa Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- NLZCOTZRUWYPTP-UHFFFAOYSA-N acacetin-7-O-beta-D-galactoside Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2OC1C(O)C(O)C(O)C(CO)O1 NLZCOTZRUWYPTP-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- VVEKCQAFOLKNKB-UHFFFAOYSA-N emodine Natural products C1=CC=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O VVEKCQAFOLKNKB-UHFFFAOYSA-N 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- GFAZHVHNLUBROE-UHFFFAOYSA-N hydroxymethyl propionaldehyde Natural products CCC(=O)CO GFAZHVHNLUBROE-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- MXEMKMNFLXVQBW-UHFFFAOYSA-N oleanoic acid Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MXEMKMNFLXVQBW-UHFFFAOYSA-N 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- GWOKWCRSUJQOMD-UHFFFAOYSA-N tilianin Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=CC=C2OC1C(O)C(O)C(O)C(CO)O1 GWOKWCRSUJQOMD-UHFFFAOYSA-N 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
Abstract
본 발명은 혈액순환 촉진용 건강식품 조성물에 관한 것으로, 구기자 9 중량%, 녹용 9 중량%, 곽향 9 중량%, 갈근 9 중량, 산수유 8 중량%, 백마 8 중량%, 사인 8 중량%, 산사자 8 중량%, 침향 8 중량%, 목향 8 중량%, 결명자 8 중량%, 복분자 8 중량%로 구성되어 혈액순환 촉진, 동맥경화, 혈액순환장해로 인한 두통의 치료에 뛰어난 효과가 있다.The present invention relates to a health food composition for promoting blood circulation, 9% by weight of wolfberry, 9% by weight of deer antler, 9% by weight of walnut, 9% by weight of cornus oil, 8% by weight of corn, 8% by weight of white horse, 8% by weight of lioness 8 Consisting of 8% by weight, 8% by weight of acupuncture, 8% by weight of neck, 8% by weight of deficiency, 8% by weight of bokbunja has an excellent effect on the treatment of headache due to blood circulation, arteriosclerosis, and blood circulation disorder.
Description
본 발명은 혈액순환 촉진용 건강식품 조성물에 관한 것이다. 더욱 상세하게는, 구기자, 녹용, 곽향, 갈근, 산수유, 백마, 사인, 산사자, 침향 , 목향, 결명자, 복분자를 혼합하여 제조함으로써 기호성이 우수하고 혈액순환 촉진에 효과가 있는 건강식품 조성물에 관한 것이다.The present invention relates to a health food composition for promoting blood circulation. More specifically, it relates to a health food composition having excellent palatability and effective in promoting blood circulation by preparing a mixture of goji berry, antler, kwak, kaleun, cornus, white horse, sine, hawthorn, acupuncture, cedar, blame, bokbunja .
정보를 교환하고 서류를 작성하기 위한 수단이 다양화짐에 따라 사무실 등의 근무처와 일 반 가정에서는 각종 사무 자동화(OA: Office Automated) 기기가 널리 확산되어 있다. OA 기기는 일반적으로 근무시에 사용자의 신체로부터 위쪽 팔을 떨어지게 하는 자세를 요구하므로 사용자가 비교적 장시간동안 사무기기를 조작함에 따라 근육 경직이 일어나서 팔, 다리, 등, 허리 등의 특정 부분에 강직현상(Stiff: 뻐근함)을 유발하게 된다. 일반적으로 근육의 강직현상은 강직부분을 마사지해 주면 쉽사리 완화시킬 수 있다. 그러나 매일 OA 기기를 조작할 경우에 있어서 강직 현상이 일단 발생하면 쉽사리 없어지지 않는다. OA 기기의 조작 외에도 육체운동,육체 노동, 부적절한 자세 및 정신적인 스트레스 등의 요인에 의해서 강직현상이 일어나기도 하고, 경부(經部) 척추증, 흉부 출구 증후군, 고혈압, 안정(眼精)피로, 자율적인 근긴장 이상 및 갱년기 장해 등의 각종 질환에 의해 일어나기도 한다. 강직 현상의 증상에 따라 특이한 완만한 통증과 불쾌감이 비교적 장기간 동안 지속하게 되고, 어떤 경우에는 두통 및/또는 구토를 수반한다.With the diversification of means for exchanging information and filing documents, office automation equipment (OA) has become widespread in offices and homes. OA devices generally require a posture that lifts the upper arm away from the user's body during work, so muscle stiffness occurs as the user operates the office equipment for a relatively long time, resulting in stiffness in certain areas such as arms, legs, back and waist. Cause stiffness. In general, muscle stiffness can be easily eased by massaging the stiffness. However, when operating the OA every day, once the stiffness occurs, it does not easily disappear. In addition to the operation of the OA, stiffness can be caused by factors such as physical exercise, physical labor, improper posture, and mental stress, cervical spondylosis, chest exit syndrome, hypertension, stable fatigue, and autonomy. It may also be caused by various diseases such as dystonia and menopausal disorders. Depending on the symptoms of stiffness, unusual mild pain and discomfort persist for a relatively long period of time, in some cases accompanied by headaches and / or vomiting.
혈액순환 (the circulation of blood)이란 혈액이 심장을 중심으로 혈관을 따라 우리의 신체를 순환하는 것으로 산소를 신체 각 조직에 공급하고 탄산가스를 방출하고, 영양소를 보급하고 대사 산물을 방출하며, 여러 내분비선에서 호르몬을 운반하여 특정기관의 기능을 조절하며 그밖에 병원균 조절작용과 체온조절, 삼투압조절, 수분조절 등의 기능을 수행하는 과정이다.The circulation of blood circulates our bodies along the blood vessels around the heart, supplying oxygen to the tissues of the body, releasing carbon dioxide, nutrients, and metabolites. The endocrine gland carries hormones to regulate the function of specific organs, and to carry out other functions such as controlling pathogens, controlling body temperature, controlling osmotic pressure, and controlling water.
혈관은 동백, 모세혈관, 정맥으로 구성되어 있다. 동맥은 외탄력선판과 결합조직으로 되어 있는 외막, 평활근이 많고 그 안에 다수의 탄력섬유를 함유하고 있는 중막, 제일 안쪽의 내피세포와 그것을 둘러싸고 있는 결합조직과 탄력섬유가 모여서 내강성판으로 되어 있는 내막으로 이루어져 있다. 모세혈관은 소동맥과 소정맥이 연결된 것으로 그물모양으로 가늘게 가지가 나 있으며 직경 0.008∼0.02mm의 가는 관으로서 적혈구가 1∼2줄로 통과될 정도이고 육안으로는 보이지 않으며, 이 모세혈관을 통해서 혈액 중의 산소와 영양분은 조직내로 보내지고 조직에서 만들어진 CO2나 노폐물은 혈관으로 들어온다. 정맥의 외막은 비교적 두껍고 내막과 중막은 얇으며 압력이 없고 다른 혈관에 비해 혈류가 약하여 심장보다 낮은 부분의 정맥에서 역류할 위험성이 있기 때문에 역류 방지용 판막(valve)이 붙어 있다.Blood vessels consist of camellia, capillaries and veins. Arteries are the outer membrane consisting of external elastic sun board and connective tissue, the mesothelial membrane with a lot of smooth muscles, containing a number of elastic fibers, the innermost endothelial cells, and the connective tissue and elastic fibers surrounding them. Consists of Capillary vessels are small arteries and small veins that are connected in a net shape and are thinly shaped with a diameter of 0.008 to 0.02 mm, and red blood cells pass through 1 to 2 lines and are not visible to the naked eye. And nutrients are sent into the tissue and the CO 2 and waste products produced by the tissue enter the blood vessels. The vein's outer membrane is relatively thick, the inner and middle membranes are thin, there is no pressure, and the blood flow is weak compared to other blood vessels.
혈액순환장애란 상기 혈관들이 탄력을 잃고 내벽에 콜레스테롤 등이 침착되어 혈관 내강이 좁아져 혈액순환이 원활치 못한 것을 말한다.Blood circulation disorder refers to blood vessels that lose their elasticity, cholesterol is deposited on the inner wall, and the lumen of the blood vessels is narrowed, resulting in poor blood circulation.
가장 대표적인 순환기계 질환으로 꼽히는 뇌졸증[중풍(中風), 풍(風)]은 뇌혈관이 터지거나 혈전이나 지방으로 막히는 것이다. 뇌졸증은 암, 심장 질환과 함께 한국인의 3대 사망원인 중의 하나이다. 뇌졸증은 뇌동맥벽이 압력 때문에 파열하여 뇌조직 내부에 혈종이 형성되어 주위의 뇌조직을 압박함으로써 생기는 출혈성 뇌졸증과, 뇌동맥의 일부가 좁아지거나 막혀서 그 동맥을 통하여 산소와 영양을 공급받아 뇌조직이 괴사를 일으키는 허혈성 뇌졸증의 두가지가 있다. 출혈성 뇌졸증은 뇌출혈과 지주막하출혈의 두가지로 더 분류되며 허혈성 뇌졸증은 뇌경색과 일과성 뇌허혈발작으로 더 분류된다.Stroke (Middle Wind, Wind), the most common circulatory disease, is the bursting of cerebrovascular vessels or clogging with blood clots or fat. Stroke is one of the three leading causes of death among Koreans, along with cancer and heart disease. Stroke is a hemorrhagic stroke caused by the rupture of the cerebral artery wall due to pressure and the formation of hematoma inside the brain tissue to compress the surrounding brain tissue, and part of the cerebral artery is narrowed or blocked, and oxygen and nutrients are supplied through the artery, leading to necrosis of the brain tissue. There are two types of ischemic stroke. Hemorrhagic stroke is further classified into two categories: cerebral hemorrhage and subarachnoid hemorrhage. Ischemic stroke is further classified as cerebral infarction and transient cerebral ischemic attack.
뇌출혈을 초래하는 보다 일반적인 증상이 고혈압과 동맥경화이다. 고혈압은 수축기 혈압이 140이상이거나 이완기 혈압이 90이상으로 지속되는 질환을 말하며 이완기 혈압이 90∼104인 경우 경중 고혈압, 105∼110인 경우 중증도 고혈압, 110이상일 때를 중증 고혈압이라고 분류한다. 전체 고혈압 환자의 90%가 원인을 알 수 없는 본태성(원발성, 일차성) 고혈압이고, 원인을 뚜렷이 알 수 있는 경우가 속발성(이차성) 고혈압이다. 혈압은 나이가 들수록 증가하며 유전적 성향이 많고, 조급한 성격, 비만, 고염분섭취, 정신적 스트레스, 흡연, 음주, 신장의 질환, 갈색 세포종, 경구 피임약의 사용, 원발성 고알도스테롤혈증 등 원인이 되어 고혈압이 발생한다.The more common causes of cerebral hemorrhage are hypertension and arteriosclerosis. Hypertension refers to a disease in which systolic blood pressure is more than 140 or diastolic blood pressure is more than 90. Mild hypertension when diastolic blood pressure is 90 to 104, severe hypertension when 105 to 110 is classified as severe hypertension. Ninety percent of all patients with hypertension are primary (primary, primary) hypertension with no known cause, and those with clear cause are secondary (secondary) hypertension. Blood pressure increases with age and is associated with genetic predispositions, hastening personality, obesity, high salt intake, mental stress, smoking, drinking, kidney disease, pheochromocytoma, the use of oral contraceptives, and primary hyperaldosterolemia. Hypertension develops.
동맥벽이 굳어져서 탄력성이 감소하고 내면에 지방이 끼이고 이상 조직이 증식하여 내경이 좁아지는 현상을 동맥경화라 한다. 다소간의 동맥경화현상은 노화 현상으로서 고령일수록 동맥경화성 질환의 빈도가 높아지며 동시에 여러 장기가 침범된 현상을 볼 수 있으며 이런 현상이 뇌혈관에서 생기면 뇌졸증이 된다. 이밖에 심장병과 당뇨병도 고혈압, 동맥경화 등과 밀접한 연관을 가진 순환기계 질환이다.Atherosclerosis is called arteriosclerosis, which hardens the arterial wall, reduces elasticity, pinches fat on the inner surface, and causes abnormal tissue to proliferate and narrow the inner diameter. Some of the arteriosclerosis is an aging phenomenon, the older the frequency of arteriosclerosis disease, the more the various organs are invaded at the same time, and this phenomenon occurs in the cerebrovascular stroke. In addition, heart disease and diabetes are also circulatory diseases that are closely related to hypertension and arteriosclerosis.
강직현상 발생 메카니즘에 대해서는 아직 명확하지 않으나, 신경의 과도한 자극, 근육피로 및 자율적인 근긴장 이상에 의해 말초혈관의 과도한 수축, 근육내에서의 혈액순환 장해, 충혈을 유발하게 되어 특이한 강직현상이 일어난다. 따라서, 근육 강직 현상을 없애기 위해서 혈액순환을 개선하는 것이 효과적이다. 마사지, 온욕(溫浴)요법, 습포제 사용, 전기자극 및 약물 투여 등의 치료방법으로서는 소요의 효과를 얻기가 어렵고, 혹은 이들 중 몇가지 환자가 전문적인 치료를 위해 병원에 가야하므로 번잡스럽다.The mechanism of occurrence of stiffness is not clear yet, but excessive stimulation of the nerves, muscle fatigue and autonomic dystonia causes excessive vascular contraction, blood circulation disorders in the muscles, and hyperemia, which causes unusual stiffness. Therefore, it is effective to improve blood circulation to eliminate muscle stiffness. Treatment methods such as massage, warmth therapy, poultice use, electrical stimulation and drug administration are difficult to obtain the effects of the disturbance, or some of them are complicated because they have to go to the hospital for professional treatment.
본 발명자는 혈액순환을 촉진할 수 있는 식품연구에 주력한 결과 천연 생약재인 구기자, 녹용, 곽향, 갈근, 산수유, 백마, 사인, 산사자, 침향, 목향, 결명자, 복분자를 혼합하여 섭취함으로써 혈액순환 촉진 효과를 얻을 수 있음을 발견하고 본 발명을 완성하였다.The present inventors focused on food research that can promote blood circulation, and promote blood circulation by ingesting natural herbal medicines such as goji berry, deer antler, kwak hyang, brown root, cornus, white horse, sine, hawthorn, acupuncture, wood fragrance, glitches, bokbunja It has been found that the effect can be obtained and the present invention has been completed.
따라서, 본 발명의 목적은 혈액순환 촉진 효과가 우수한 건강식품 조성물을 제공함에 있다.Accordingly, an object of the present invention is to provide a health food composition excellent in blood circulation promoting effect.
본 발명의 상기 목적은 천연 약재들을 구기자 9 중량%, 녹용 9 중량%, 곽향 9 중량%, 갈근 9 중량, 산수유 8 중량%, 백마 8 중량%, 사인 8 중량%, 산사자 8 중량%, 침향 8 중량%, 목향 8 중량%, 결명자 8 중량%, 복분자 8 중량%로 혼합하여 혈액순환 촉진용 건강식품 조성물을 제조하고, 상기 조성물을 사용하여 동물실험을 실시하여 혈액순환 촉진, 동맥경화 억제 및 진통작용효과를 측정함으로써 달성하였다.The above object of the present invention is natural herbs 9% by weight, antler 9% by weight, balsam 9% by weight, brown root 9%, cornus 8% by weight, white horse 8% by weight, 8% by weight sasa, 8% by weight of lioness, aroma 8 To prepare a health food composition for promoting blood circulation by mixing in weight%, neck weight 8% by weight, 8% by weight deflector, 8% by weight bokbunja, animal experiments using the composition to promote blood circulation, inhibit arteriosclerosis and pain relief Achieved by measuring effect.
이하 본 발명의 구체적인 구성 및 효과를 실시예를 들어 설명하지만 식품종류의 선택 및 조성비의 변경 등은 건강식품의 효과를 저하시키고 당업자간에 권리의 범위를 의도적으로 무의미하게 변경을 꾀할 수 있음은 물론이며 이와 같은 수치 범위의 변경은 본 발명의 권리범위 내 속하는 것은 물론이다.Hereinafter, the specific configuration and effects of the present invention will be described with reference to examples, but the selection of food types and the change in composition ratio may deteriorate the effects of health foods and intentionally and intentionally change the scope of rights among those skilled in the art. Of course, such a change in numerical range is within the scope of the present invention.
본 발명의 바람직한 실시예에 따르면, 구기자 9 중량%, 녹용 9 중량%, 곽향 9 중량%, 갈근 9 중량, 산수유 8 중량%, 백마 8 중량%, 사인 8 중량%, 산사자 8 중량%, 침향 8 중량%, 목향 8 중량%, 결명자 8 중량%, 복분자 8 중량%를 잘게 분쇄하여 분말로 가공한 다음 혼합하여 분말을 가공한다.According to a preferred embodiment of the present invention, 9% by weight of wolfberry, 9% by weight of deer antler, 9% by weight of balsam, 9% by weight of brown root, 8% by weight of cornus oil, 8% by weight of white horse, 8% by weight of hawthorn, 8% by weight of hawthorn, aroma 8 The powder is processed by pulverizing finely divided by weight, 8% by weight of wood, 8% by weight of deficiency, and 8% by weight of bokbunja.
구기자(Lycinm chinense Miller)는 구기자나무의 열매로 비타민 0.1%, 카로티노이드인 제아크산틴, 생물학적활성물질인 스코폴레틴이 있고, 열매껍질에서 피살리엔이 분리되었다. 구기자는 혈압내림작용, 항지간작용, 간기능보호작용을 하여 동맥경화 예방 및 치료, 보약, 염증약, 열내림약으로 폐결핵, 당뇨병에 사용한다. 동의치료에서는 열매를 보약으로 허리아픔, 무력증, 어지럼증, 머리아픔, 소갈에 쓰며 오래 먹으면 뼈를 든든하고 몸을 가볍게 하여 흰머리를 검게 하고 눈을 밝게 하며 추위와 더위도 타지 않고 오래 산다는 말이 전해오고 있다.Gojija (Lycinm chinense Miller) is the fruit of the Goji berry, vitamin 0.1%, carotenoids zeaxanthin, biologically active scopoletin, and the pisalien from the fruit peel. Goji is a blood pressure lowering action, anti-interstitial action, liver function protection action to prevent and treat atherosclerosis, as a medicine, inflammatory drugs, heat lowering drugs used in pulmonary tuberculosis, diabetes. In motion therapy, the fruit is used as a supplement to lower back pain, helplessness, dizziness, head pain, and small meals. .
산수유(Macrocarpium officinale Sieb. et Zucc.)는 산수유나무 열매껍질로 열매에는 결정성유기산, 몰식자산, 사과산, 포도주산 등이 있으며 열매껍질에는 이리도이드배당체인 모르로니시드, 로가닌 등이 있다. 동의치료에서는 자양강장약, 수렴약으로 콩팥을 보하며 땀을 자주 흘리고 오줌이 조금씩 자주 나올 때, 허리아픔, 달거리가 고르지 않을 때 사용한다.Cornus (Macrocarpium officinale Sieb. Et Zucc.) Is a fruit bark of the hawthorn tree, which includes crystalline organic acids, glutinous assets, malic acid, and grape acids, and the fruit shells include iridonide glycosides such as moronisides and loganins. In motion therapy, nourishment tonic and astringents are used to see the kidneys, and when sweating frequently and urine comes out little by little, it is used when the back pain and the moon are uneven.
녹용은 사슴과(Cornu cervi)에 속하는 사슴의 각화되지 않은 유각을 채취하여 건조시킨 것으로, 한방에서 인삼과 더불어 가장 널리 사용하고 있는 생약 중의 하나이다. 녹용에는 유리아미노산, 헥소사민, 우론산, 시알산, 히포크산틴, 에스트론, 에스트라디올 리셉터 등의 성분이 함유되어 있다. 녹용은 강장작용, 생장. 발육 촉진작용, 조혈작용, 신경쇠약 치료작용, 심부전증 치료작용, 오장육부의 기능 항진 작용 등 다양한 효능이 있는 것으로 동의보감에 수록되어 있으며, 그 외에도 자양보신, 신체활력 증강 및 심근운동 개선 등의 효과와, 피로회복, 신체 저항력 증진, 건뇌안신 효과 등이 있다.Deer antler is an unhorned shell of a deer belonging to the family Cornu cervi, which is one of the most widely used herbal medicines with ginseng. Deer Antler contains components such as free amino acid, hexosamin, uronic acid, sialic acid, hypoxanthine, estrone, estradiol receptor, and the like. Deer Antler is tonic, growth. It has various effects such as development promotion, hematopoiesis, nervous breakdown treatment, heart failure treatment, hypertrophy of five intestines, etc. , Fatigue recovery, physical resistance enhancement, psoriasis anesthesia effect.
방아풀[Agastache rugosa(Fisher et Meyer) O. Kuntze]이라 불리우는 곽향은 높이 1∼1.5m에 이르는 여러해살이풀로 정유는 전초에 약 0.3%, 잎에 0.2∼2.3%,꽃이삭에 5%, 줄기에 0.1% 있다. 정유의 주성분은 메틸카비골, 아니스알데히드, 아네톨, d-리모넨, 세스쿠이테르펜, α-피넨, β-피넨, α-리모넨, 옥사논, P-찌몰, 리날롤이 있고, 플라보노이드로서 아카쩨틴, 틸리아닌, 리나린, 아가스타코시드가 분리되었다. 동의치료에서 건위약, 구풍약, 소화약, 열내림약으로 더위를 먹거나 먹은 것이 체한 때, 감기, 머리아픔과 구토설사때 쓴다. 또한 피질병, 종양치료약으로도 드물게 사용하며 특히, 비장과 위장병에 쓰이는 중요한 약이다.Called Agastache rugosa (Fisher et Meyer) O. Kuntze, the perennial herb is 1-1.5m high, essential oil is about 0.3% for outpost, 0.2-2.3% for leaves, 5% for flowers, 0.1% on the stem. The main components of essential oils are methylcarbigol, anisealdehyde, anetol, d-limonene, sesquiterpene, α-pinene, β-pinene, α-limonene, oxanone, P-chimol, linalol, and acachettin as flavonoid , Tilianin, linarin, and agathacoside were isolated. In motion therapy, it is used for cold, head pain and vomiting diarrhea when eating or eating heat with dry stomach medicine, old wind medicine, digestive medicine, heat lowering medicine. It is also rarely used for the treatment of cortical diseases and tumors.
백마는 천마의 자구로 천마와 영양분을 서로 섭취하며 공생 생장시켜 한약에서 간질병, 중풍, 경기, 두통, 강장, 신경질환 치료의 특효약이다. 덩이뿌리에 P-히드록시벤질알콜과 그 배당체 가스트린, P-히드록시벤질알데히드 등이 분리되며, 동의치료에서 강장약, 진정, 진경약으로 어지러움, 메스꺼움, 전간, 신경쇠약, 게우기, 신경장애로 말을 못할 때, 팔다리의 경련과 마비, 말초신경장애 등에 쓰인다. 신경을 든든하게 하며 피를 보하고 머리를 검게 한다는 말이 전해져오고 있다. 또한 오줌내기약으로 콩팥염, 기타 당뇨병, 고혈압, 성기능장애, 육체적 피로 등에도 쓴다. 특히 어린이들의 경련에 많이 쓰인다.White horse is a natural horse chestnut and nourish each other. It is a medicinal medicine for the treatment of epilepsy, stroke, game, headache, tonic and neurological diseases in Chinese medicine. P-hydroxybenzyl alcohol, its glycosides, gastrin, P-hydroxybenzylaldehyde, etc. are separated from the roots, and dizziness, nausea, cramps, nerve pain, cramps, and nerve disorders in tonic, sedative, and antifungal drugs in motion therapy. When you can not speak, it is used for cramps and paralysis of the limbs and peripheral neuropathy. Words have been said to strengthen the nerves, look at the blood and blacken the head. It is also used for urinary tract drugs, other diabetes, high blood pressure, sexual dysfunction, and physical fatigue. Especially used for cramps in children.
높이 1.3∼2m에 이르는 여러해살이풀인 축사(Amomum xanthioides Wallich.)의 열매인 사인은 동의치료에서 배가 아프고 불룩하며 먹은 것이 내려가지 않고 메스꺼우면서 토할 때, 설사할 때 한번에 2∼3g을 사용한다.Sine, a fruit of the perennial Amomum xanthioides Wallich., Which has a height of 1.3 to 2 m, uses 2 to 3 g at one time when diarrhea vomits while the stomach is sore, swollen, and eaten without falling down. .
산사자는 모과 열매처럼 쿠엘세틴, 오레아놀산을 함유하고 있기 때문에 이뇨작용을 하며, 비타민 B, C, 칼로틴, 클로로겐산 등을 함유하고 있어 산후복통, 숙취, 건위, 소화불량, 만성 설사에 효과적이고 위장의 활동을 조절하고 소화불량을치료하는 효과도 있다.The hawthorn is diuretic because it contains quercetin and oleanoic acid like quince, and it contains vitamin B, C, carotene and chlorogenic acid, which is effective for postpartum abdominal pain, hangover, dryness, indigestion and chronic diarrhea. It is also effective in controlling gastrointestinal activity and treating indigestion.
침향(Aquillaria Agallocha Roxburgh)은 높이 30m에 이르는 사철푸른 나무로 이 식물의 목질부에는 수지가 없으나 상처를 입거나 썩게 되면 수지가 생겨나서 상처를 보호한다. 이렇게 수지가 생긴 나무를 베서 흙속에 묻거나 자연적으로 썩게 하여 수지가 없는 부분을 없앤 것을 침향, 침수향(Lignum Aloes)이라고 한다. 침향을 알칼리로 비누화한 다음 수증기증류하면 13%의 정유가 얻어진다. 동의치료에서는 매스껍고 토할 때, 배가 아플 때, 천식 때 한번에 1.5∼3g을 쓴다. 나무속살은 방향성건위구풍약으로 사용한다.Aquillaria Agallocha Roxburgh is a 30 m high evergreen tree with no resin in the wood of the plant, but when wounded or rotted, it forms a resin that protects the wound. This type of incense, submerged incense (Lignum Aloes) is to remove the resin-free parts by cutting the resin-like wood in the soil or to naturally rot. Saponification of the fragrance with alkali followed by steam distillation yields an essential oil of 13%. In motion therapy, you can use 1.5 to 3 grams at one time when you are nauseous and vomiting, when your stomach hurts and asthma. The bark is used as a directional dry wind.
목향(Inula Helenium L.)은 높이 50∼150㎝에 이르는 여러해살이풀로 뿌리줄기와 뿌리에는 1∼5%의 정유가 있고, 이 정유를 식히면 결정이 생기는데 이를 헬레닌이라고 한다. 또한 정유에는 헬레닌 외에도 트리테르펜알콜인 다미라디에닐아세타트 C32H52O2, 적은량의 알란톨 C15H23O2, 프로아줄렌이 있다. 뿌리에는 이눌린, 프세우도이눌린, 이눌레닌, 사포닌, 쓴맛물질, 색소, 훈적의 알칼로이드가 있으며, 안란톨은 신선한 뿌리에 있다. 동의치료에서는 가래약, 건위약, 오줌내기약, 땀내기약으로 상기도카타르, 기관지염, 폐결핵 등 여러 가지 호흡기 질병에 쓰이며, 구토, 설사, 배아픔, 위카타르, 위액의 산도가 낮을 때와 감기에도 쓰인다.Mokhyang (Inula Helenium L.) is a perennial herb that grows from 50 to 150 centimeters in height and contains 1 to 5 percent of essential oils in the stem and roots. When this essential oil is cooled, crystals are called helenin. In addition to helenin, essential oils include triterpene alcohol, dimiradienylacetate C 32 H 52 O 2 , small amounts of allantol C 15 H 23 O 2 and proazulene. Roots include inulin, pseudoinulin, inulinen, saponin, bitter substances, pigments, and fuco alkaloids. Anantol is in the fresh root. In motion therapy, sputum, dry stomach, urinary medicine, and sweating medicine are used for various respiratory diseases such as upper catarrhal, bronchitis, and pulmonary tuberculosis. .
갈근은 칡(Pueraria lobata Ohwi)의 뿌리로 여기에는 이소플라본화합물인 다이드제인 C15H10O4, 다이드진 C21H20O9, 푸에라린 C21H20O9, 푸에라린크실로시드, 루테올린, 비오카닌 A, C16H12O5등과 농마, 쿠마린이 있다. 또한 콜린, 아세틸콜린양물질,카크코네인, 푸에라롤이 갈라졌다. 동의치료에서 발한해열약, 진경약으로 열병에 쓰며 목안이 마르고 머리가 아플 때, 감기로 머리와 목이 아플 때, 편도염, 급성중이염에 쓴다. 또한 소갈병, 열이 나고 게우며 머리가 아프고 속이 답답한데, 목과 어깨가 뻗뻗한 때 그리고 어혈을 풀고 상처를 아물게 하는데 쓰인다. 또한 고혈압, 폭발성귀울이때 사용하며 농마와 섞어서 열내림약으로 쓴다.Puerariae Radix is a root of kudzu (Pueraria lobata Ohwi) This isoflavone compound daidzein C 15 H 10 O 4, daidzin C 21 H 20 O 9, Puerto rarin C 21 H 20 O 9, rarin Puerto Xyloxide, luteolin, biocanin A, C 16 H 12 O 5 and the like, and horses, coumarin. In addition, choline, acetylcholine-positive substances, cacaine, and puerarol cracked. It is used for fever as antipyretic medicine and sensitizing medicine in the treatment of motion. It is also used for hunger, fever, swelling, pain in the head and stuffy stomach, when the neck and shoulders are stretched out, and used to loosen the blood and heal the wound. It is also used for high blood pressure and explosive tinnitus.
결명자는 결명초(Cassia obtusifolia L.)의 씨로 에모딘, 오브투시폴린, 오브투신 C18H16O7, 크리소오브투신 C19H18O7, 아우란티오오브투신 C17H14O7과 그 배당체가 분리되었다. 결명자의 물 또는 알콜추출물은 동물실험에서 혈압낮춤작용이 있으며 동의치료에서는 신장을 보호하며 간열을 내리우고, 거풍, 열내림 효과가 있다고 하여 바람으로 머리가 아프며 눈병을 치료하는데 쓰인다.The defector is the seed of Cassia obtusifolia L., Emodine, Obtufofolin, Obtucin C 18 H 16 O 7 , Chrysoobtucin C 19 H 18 O 7 , Aurantioobtucin C 17 H 14 O 7 And its glycosides were separated. The water or alcohol extracts of the deficiency have a blood pressure-lowering effect in animal experiments. In motion therapy, it protects the kidneys, lowers the liver fever, and has the effect of wind and pain.
복분자는 멍덕딸기(Rubus sachalinensis Lev.)의 선열매로 2.2%의 레몬산을 비롯한 유기산, 살리찐산, 카프론산, 개미산과 그의 염, 많은량의 펙틴, 카로틴(0.3㎎%), 비타민 B군, 포도당 4.3%, 과당 8%, 서당 6.5%, 탄닌질 0.3%, 찌아니딘클로리드 C27H31O6, 아세토인 C4H8O2, β-요논, 벤즈알데히드가 있다. 복분자 달임약은 동물실험에서 열내림작용과 강심이뇨작용을 하며, 동의치료에서는 복분자를 발한해열약으로 감기, 열성질병, 폐염, 기침, 강정강장약으로 쓴다.Bokbun is a fruit of Rubus sachalinensis Lev., Organic acid including 2.2% lemon acid, salinic acid, capronic acid, formic acid and salts thereof, large amount of pectin, carotene (0.3mg%), vitamin B group, glucose 4.3%, 8% fructose, 6.5% sucrose, 0.3% tannin, thianidine chloride C27H31O6, acetoin C4H8O2, β-nonone, benzaldehyde. Bokbunja decoction is a fever lowering effect and cardiac diuresis in animal experiments. In motion therapy, Bokbunja antipyretic fever is used as cold, febrile disease, pneumonia, cough, and gangjeong tonic.
본 발명은 식품으로 인체에 전혀 해롭지 않고 우리가 항상 먹고 있는 식품원료 중에서 들에서 자생하고 있는 가식성(edible) 식품원료인 구기자, 녹용, 곽향, 갈근, 산수유, 백마, 사인, 산사자, 침향 , 목향, 결명자, 복분자를 미세하게 분쇄한 후, 건조하여 혼합분말가루로 만든 것으로, 인체에 해로운 것이 없고 그 성분 중에는 혈액순환 촉진 등 신진대사 작용에 관여하는 것이 있으므로 유용한 것이다.한편, 본원발명의 구성으로부터 발생하는 효과를 보건대, 본원발명은 서로 다른 12개의 한약재를 혼합함으로써 혈액순환촉진의 효과가 발생한다. 그런데 이러한 효과는 본원발명의 구성요소들의 각각으로부터 발생되는 효과가 아니라 상기 구성요소들이 서로 유기적으로 결합되어 발생하는 효과이다.The present invention is a food is not harmful to the human body at all, we are always edible food raw materials that are grown in the field of the edible food (edible), antler, kwak hyang, kaleun, cornus, white horse, sign, hawthorn, incense, throat It is useful because it is finely pulverized, dried, powdered, dried, powdered, powdered, powdered, and powdered, which is not harmful to the human body, and is involved in metabolic actions such as promoting blood circulation. In view of the effects that occur, the present invention is the effect of promoting blood circulation by mixing 12 different herbal medicines. However, this effect is not an effect generated from each of the components of the present invention, but is an effect caused by the organic components combined with each other.
즉, 본원발명에 있어 혈액순환기능의 조된 구성성분으로 기운을 조리하고 기운을 소통시켜 막힌 부위를 제거시켜 혈액순환을 도와주는 약물로 목향, 침향이 사용되고, 방향성이 있어 기체에 원인이 되는 습기를 제거하고 소화기를 보호하여 혈액순환을 도와주는 곽향, 공사인, 산사자가 사용되는데, 많이 복용하거나 오래도록 복용을 하면 쉽게 진액(좋은물질)을 손상시키고, 정기를 소모시키므로 손상된 진액을 보충하기 위하여 갈근, 구기자를 첨가하고, 정기의 소모를 보충하기 위하여 녹용, 복분자를 첨가하고, 정기의 소모와 진액의 손상을 보충하기 위해 산수유를 첨가하고, 기운이 함부로 운행되는 것을 방지하면서 진액 손상이나 정기의 손실이 안 되게 백마, 결명자를 보충한다.본 발명의 건강식품 조성물에 함유되는 성분은 모두 생약재, 식품재료 및 식품으로 사용되는 것으로, 복용 또는 섭취시 인체에 대한 안전성이 우수하다.That is, in the present invention, as a drug that cooks energy as a cooperative component of the blood circulation function and communicates energy to remove clogged areas to help blood circulation, neck and aroma are used, and the odor causes moisture to cause gas. Kwakhyang, construction workers and mountain lions are used to help the blood circulation by removing and protecting the digestive organs. If you take a lot or take it for a long time, it easily damages the essence (good substance) and consumes it regularly. Add goji berry, add antler and bokbunja to replenish regular consumption, add cornus oil to replenish regular consumption and damage of essence, and prevent damage to fluid and prevent loss of essence White horses and missing people are supplemented. The ingredients contained in the health food composition of the present invention are all herbal medicines, foods To be used as fuel and food intake when taking or excellent safety for the human body.
본 발명에 따른 바람직한 식품 조성물의 제형은 통상의 방법에 따라 분말화한 것이지만, 열수 또는 유기용매로 추출하여 담체를 넣어 건조한 후 캡슐화 하거나 기타 정제, 과립, 분말, 음료, 죽 등의 형태로 제형화할 수 있다.The formulation of the preferred food composition according to the present invention is powdered according to a conventional method, but is extracted with hot water or an organic solvent, dried with a carrier, then encapsulated, or formulated in the form of other tablets, granules, powders, beverages, porridge, and the like. Can be.
본 발명 혈액순환 촉진용 건강식품 조성물의 바람직한 실시예를 들면 다음과 같다.Examples of the health food composition for promoting blood circulation of the present invention are as follows.
실시예 1 : 혈액순환 촉진용 조성물(단위 : 전체 100에 대한 중량%)Example 1 Composition for Promoting Blood Circulation (Unit: Weight% of Total 100)
구기자 9 중량%Wolfberry 9% by weight
녹용 9 중량%Deer Antler 9% by weight
곽향 9 중량%Outline 9% by weight
갈근 9 중량Root weight 9
산수유 8 중량%Cornus 8% by weight
백마 8 중량%8% by weight of white horse
사인 8 중량%Sine 8% by weight
산사자 8 중량%Sun Lion 8% by weight
침향 8 중량%Aroma 8 wt%
목향 8 중량%8% by weight
결명자 8 중량%8% by weight of defector
복분자 8 중량%Bokbunja 8 wt%
이하, 본 발명의 실시예에 따른 혈액순환 촉진 효과를 측정하기 위한 동물실험 및 인체에 적용한 임상학적 실험과 그 결과를 제시한다.Hereinafter, an animal experiment for measuring blood circulation promoting effect according to an embodiment of the present invention and clinical experiments applied to the human body and the results are presented.
실험예 1 : 혈액순환 촉진 효과 실험(동물실험)Experimental Example 1: Blood circulation promoting effect experiment (animal experiment)
본 발명 혈액순환 촉진용 건강식품 조성물의 혈관확장효과를 측정하기 위하여 쥐(rats)의 하지동맥을 이용하여 KCl 유도 혈관수축에 대한 확장효과를 physiography로 측정하였다.In order to measure the vasodilation effect of the blood food promoting health food composition of the present invention, the expansion effect on KCl-induced vasoconstriction was measured by using the lower limb arteries of rats.
실험동물로는 체중 20∼25g 내외의 스프라그-돌리(Sprague-Dawley)계 흰쥐(rat)를 항온, 항습이 유지되는 동물사육실에서 1주일 이상 적응시킨 후, 일반상태를 관찰하여 외관상 건강한 동물을 선별하여 10마리씩 2군(二群)으로 나누어 정상 대조군에게는 은행잎 엑기스를 급여하였고, 실험군에게는 본 발명 혈액순환 촉진용 건강식품 조성물을 식염수에 용해시켜 체중 250g당 0.14㎎으로 1일 1회 복강으로 급여하였다.As experimental animals, Sprague-Dawley rats with a body weight of about 20 to 25 g were allowed to acclimate for at least one week in an animal breeding room maintained at constant temperature and humidity. Selected and divided into two groups (10 씩 each), the normal control group was fed ginkgo biloba extract, the experimental group was dissolved in saline solution of the health food composition for promoting blood circulation of the present invention and fed once per day at 0.14mg per 250g body weight It was.
실험결과 표 1에 나타낸 바와 같이, KCl 72.7mM 유도 혈관수축에 대한 본 발명 혈액순환 촉진용 건강식품 조성물이 은행잎 엑기스보다 혈관확장효과가 뛰어남을 확인할 수 있었다.As shown in Table 1, it was confirmed that the present invention blood circulation promoting health food composition for KCl 72.7mM induced vasoconstriction has a superior vasodilation effect than ginkgo leaf extract.
실험예 2 : 동맥경화 억제효과 측정Experimental Example 2 Measurement of Inhibition of Arteriosclerosis
상기 실험예 1에서 선별한 웅성흰쥐 10마리를 1군으로 하여 정상군에는 올리브유만을, 대조군에는 콜레스테롤 40m/㎏과 콜레칼시페롤 3200 IU/㎏을 동시에 올리브유에 용해시켜 28일동안 1일 1회 경구투여하여 동맥경화증을 유발시켰다. 여기에 본 발명 혈액순환 촉진용 조성물을 각각 0.250 g/㎏의 농도로 7일동안 후처리하였다. 처리방법은 1일 1회 경구투여하고, 정상군과 대조군에는 동량의 생리식염수를 동일한 방법으로 경구투여하였다.Ten male rats selected in Experimental Example 1 were used as the first group, and only olive oil was used in the normal group, and 40 m / kg cholesterol and 3200 IU / kg cholesterol were simultaneously dissolved in olive oil once a day for 28 days. Oral administration caused atherosclerosis. Here, the blood circulation promoting composition of the present invention was post-treated for 7 days at a concentration of 0.250 g / kg, respectively. The treatment method was orally administered once a day, and the same amount of normal saline was administered orally to the normal group and the control group.
실험 최종일에 정상군과 대조군을 12시간동안 절식시킨 후 우레탄마취하에서 복대동맥으로부터 채혈하였다. 얻은 혈액을 3000rpm 하에서 15분간 원심분리하여 용혈되지 않은 혈청을 채취한 다음, 효소법에 의하여 총 콜레스테롤의 함량, 총 콜레스테롤 중에 함유된 HDL-콜레스테롤의 함량을 측정하였으며, 혈청 중의 트리글리세라이드의 함량과 칼슘함량은 각각 측정용 키트(kit)를 사용하여 측정하였다. 실험결과는 표 2에 나타낸 바와 같다.On the last day of the experiment, the normal and control groups were fasted for 12 hours, and blood was collected from the abdominal aorta under urethane anesthesia. The obtained blood was centrifuged at 3000 rpm for 15 minutes to collect serum that was not hemolyzed, and then the total cholesterol content and HDL-cholesterol content in total cholesterol were measured by enzyme method, and triglyceride content and calcium content in serum were measured. Were each measured using a kit for measurement. The experimental results are shown in Table 2.
실험예 3 : 진통작용효과 측정Experimental Example 3 Measurement of Analgesic Effect
진통작용을 갖는 물질을 스크리닝하는 방법으로 가장 많이 사용하는 것이 초산을 이용한 라이팅(acetic acid induced writhing) 실험법이다[Niemegeers, et al. Drug-Res. 1505(1975)]. 약물을 피하투여하고 30분 후에 1.0%의 초산을 체중당 0.1 mL/10g 씩 복강으로 주사하면 뒷발을 쭉 뻗는 상태인 writhing을 보이는데, 약물투여 후 10분후부터 10분간 writhing 횟수를 측정하는 방법이다.The most commonly used method for screening analgesic substances is acetic acid induced writhing (Niemegeers, et al. Drug-Res. 1505 (1975). After 30 minutes of subcutaneous administration, 1.0% acetic acid was injected intraperitoneally with 0.1 mL / 10g per body weight to show writhing, which extends the hind foot, which is a method of measuring the number of writhings for 10 minutes from 10 minutes after drug administration.
본 실험예에서는 상기 실험예 1 및 2에서 선별한 쥐를 대조군과 본 발명 혈액순환 촉진용 조성물 투여군에 각각 10마리씩 사용하였다. 대조군에는 식염수를 투여하였고, 본 발명 혈액순환 촉진용 조성물 투여군에는 조성물을 0.9% 식염수에 현탁하여 20㎎/㎏/day씩 2주동안 투여하였고, 7일에 한번씩 동일한 시간에 writhing를 측정하였다. 실험결과 표 3에 나타낸 바와 같이, 본 발명 혈액순환 촉진용 건강식품 조성물이 혈액순환장해로 인한 두통에 대하여 진통작용을 나타냄을 확인할 수 있었다.In this experimental example, 10 rats selected from Experiments 1 and 2 were used in the control group and the administration group of the present invention for promoting blood circulation. Saline was administered to the control group, the composition for administration of the blood circulation promoting composition of the present invention, the composition was suspended in 0.9% saline and administered for 2 weeks at 20 mg / kg / day, and writhing was measured at the same time every 7 days. Experimental results As shown in Table 3, it was confirmed that the present invention blood circulation promoting health food composition exhibits analgesic action against the headache caused by blood circulation disorder.
이상의 실시예와 실험예에서 설명한 바와 같이 본 발명에 따르면 상기의 혈액순환 촉진용 건강식품을 제공하고, 사용한 경우 부작용 없이 사용자에게 만족감을 주는 뛰어난 효과가 있으며 혈액순환의 촉진, 동맥경화, 혈액순환장해로 인한 두통의 치료에 뛰어난 효과가 있으므로 건강식품산업상 매우 유용한 발명인 것이다.According to the present invention as described in the above examples and experimental examples, the present invention provides a healthy food for promoting blood circulation, and when used, has an excellent effect of satisfying the user without side effects, and promotes blood circulation, arteriosclerosis, and blood circulation disorder. Because of the excellent effect in the treatment of headaches is a very useful invention in the health food industry.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0045721A KR100376306B1 (en) | 2000-08-07 | 2000-08-07 | Healthy food for promoting the circuration of the blood |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0045721A KR100376306B1 (en) | 2000-08-07 | 2000-08-07 | Healthy food for promoting the circuration of the blood |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020012435A KR20020012435A (en) | 2002-02-16 |
KR100376306B1 true KR100376306B1 (en) | 2003-03-17 |
Family
ID=19682122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-0045721A KR100376306B1 (en) | 2000-08-07 | 2000-08-07 | Healthy food for promoting the circuration of the blood |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100376306B1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100438417B1 (en) * | 2000-12-14 | 2004-07-02 | 김영식 | Manufacturing method for health-care food mainly using the medicinal material of SANSUYU |
KR100447948B1 (en) * | 2001-02-27 | 2004-09-08 | 한국생명공학연구원 | Agastache rugosa Extract for anti-inflammatory activity and anti-atherogenic activity |
KR101345336B1 (en) * | 2007-01-31 | 2013-12-30 | 한국 한의학 연구원 | Composition for enhancing blood circulation containing modified Jeho-Tang extract as an active ingredient |
KR102339923B1 (en) * | 2019-11-12 | 2021-12-20 | 한국한의학연구원 | Food therapy Jeho-Tang composition for enhancing blood circulation |
KR102466832B1 (en) | 2020-09-18 | 2022-11-15 | 천지인초 주식회사 | Functional food composition having cranial nerve protection effect and blood flow improvement effect |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000014758A (en) * | 1998-08-25 | 2000-03-15 | 김관식 | Health pillow |
-
2000
- 2000-08-07 KR KR10-2000-0045721A patent/KR100376306B1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000014758A (en) * | 1998-08-25 | 2000-03-15 | 김관식 | Health pillow |
Also Published As
Publication number | Publication date |
---|---|
KR20020012435A (en) | 2002-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6077554B2 (en) | Wrapping fermentation method using medicinal flowers and skin external preparation composition using the method | |
KR101090284B1 (en) | Tonic comprising red ginseng and deer antlers extracts and manufacturing method thereof | |
KR20160087114A (en) | Food additive containing flowers | |
KR20110129673A (en) | Herbal composition for removing hangover and beverage containing the same | |
KR20160087112A (en) | Flower tea and method for manufacturing therof | |
JP2003192605A (en) | Lipase inhibitant | |
KR20160087113A (en) | Cosmetics containing flowers | |
KR100947278B1 (en) | A carbohydrate and lipid absorption inhibitory nelumbo composition and its manufacturing process thereof | |
WO2015018129A1 (en) | Antihypertensive chinese medicine preparation and preparation method therefor | |
KR100731160B1 (en) | Crude drugs composition for accelerating recovery of bone fracture | |
KR20090127970A (en) | Uncooked food pill and its manufacturing process | |
CN104306659B (en) | A kind of Chinese medicine composition for treating diabetes B | |
WO2015018124A1 (en) | Traditional chinese medicine preparation for reducing blood pressure and preparation method thereof | |
KR20020006062A (en) | Powdered composition of health food having an effect against a stomach disorder | |
KR101456937B1 (en) | Composition comprising the extracts of natural material for controling or treating obesity | |
KR100376306B1 (en) | Healthy food for promoting the circuration of the blood | |
KR20110019569A (en) | Composition of health food | |
CN103417886B (en) | A kind of Chinese medicine composition for the treatment of bronchial asthma and preparation method thereof | |
KR100712659B1 (en) | Herbal composition for treatment and prevention of diabetes and diabetic complications | |
KR102058298B1 (en) | Method for manufacturing hangover curing agent | |
KR20190029971A (en) | Herbal composition for the prevention and treatment of coronary heart disease | |
US6444236B1 (en) | Compositon containing medicinal herbs and young antlers of cornu cervi | |
KR102111836B1 (en) | the natural composite with the functon of rheumatoid athritis protection and treatment | |
KR20120024186A (en) | A composition of health supplementary food and method thereof | |
CN106265416A (en) | Chinese herbal medicine hair care curry water |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20090305 Year of fee payment: 7 |
|
LAPS | Lapse due to unpaid annual fee |